Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News

Recombinant Antibody Products

Creative Biolabs is a pioneer of recombinant antibody (rAb) discovery and manufacture, providing the most comprehensive list of rAb products in the world. We have developed proprietary procedures for Hi-Affi™ recombinant antibody production, with optimized library construction and screening processes using hybridoma or phage display technology.

Learn More

Functional Antibody Products

At Creative Biolabs, our functional antibody products are produced and purified using specialized techniques, offering numerous features suitable for research in the activation, blocking, and neutralization of immune cell functions.

Learn More

Engineered Antibody Products

Creative Biolabs provides a diverse range of engineered antibody products, dedicated to providing clients with effective, precise, and safe antibody solutions. Our products use advanced antibody screening and engineering techniques, ensuring each one has exceptional specificity for accurately identifying targets while minimizing interference from non-specific binding.

Learn More

High Throughput Antibody Production Services

Creative Biolabs has launched high-throughput antibody production services, delivering quality antibody products to clients worldwide efficiently and rapidly. Till now, our platform has been meticulously constructed to encompass a broad range of antibody formats, from single-domain antibodies to full-length IgGs.

Learn More
30Apr/23
Recombinant Antibody

Scientists Reviewed the Advances, Challenges and Countermeasures in Immunotherapy of Gastrointestinal Tumors

April 30, 2023Cancer Immunotherapy, NewsGastrointestinal Tumor, immunotherapybiorab

The morbidity and mortality of intestinal tumors are among the top malignant tumors, and they are major diseases that seriously threaten people’s health. The prognosis for some patients with gastrointestinal malignancies hasRead More…

12Mar/23

Released! Mechanisms Behind Immune Cells’ Responses to Cancer Cell Mutations

March 12, 2023Cancer Immunotherapy, NewsCancer Immunotherapybiorab

Neoantigens are peptides derived from nonsynonymous mutations in human leukocyte antigens (HLAs) that are recognized by antitumor T cells. The large diversity of HLA alleles and limited clinical samples often narrow scientists’Read More…

22Feb/23

The Ineffectiveness of Cancer Immunotherapy May Be Due to the Lack of Specific Key Immune Cells in Patients

February 22, 2023Cancer ImmunotherapyCancer Immunotherapybiorab

Nowadays, immunotherapy has dramatically changed the care of cancer patients. In the case of patients with advanced melanoma, one of the most lethal cancers of human skin, the 5-year survival rate hasRead More…

02Jan/23

Scientists Discovered the Key Molecule Triggering Cancer Metastasis

January 2, 2023Cancer Immunotherapy, NewsCancer Immunotherapybiorab

Many cancer cells never leave their original tumor tissue. Some cancer cells have evolved the ability to migrate to other tissues, but they will become dormant once they are unable to formRead More…

05Dec/22

Transcriptional and Immunophenotypic Profiling Reveals Molecular and Immunological Features of Cancer Tumourigenesis

December 5, 2022Cancer Immunotherapy, NewsCancer Immunotherapybiorab

The paradigm of the adenoma-cancer sequence has typically focused on cancer cells in colorectal cancer (CRC) development that is already validated to entail heterologous interactions between altered cells and their surrounding microenvironment.Read More…

14Oct/22

An Optimal Combination Therapy with Broadly Neutralizing Antibodies Shows Promise in Stopping HIV Escape and Rebound

October 14, 2022Recombinant Antibody R&D, Therapeutic Antibody R&Dtherapeutic antibodybiorab

In a recently published study, researchers from the Max Planck Institute for Dynamics and Self-Organization in Germany, the University of Cologne, and the University of Washington found that a carefully designed mixtureRead More…

01Oct/22

European Commission Approved Long-Acting Antibody Therapy Evusheld for the Treatment Against COVID-19

October 1, 2022Therapeutic Antibody R&Dtherapeutic antibodybiorab

AstraZeneca recently announced that the European Commission (EC) has approved its long-acting antibody therapy Evusheld (tesaglizumab in combination with cilgravizumab, formerly AZD7442) for the treatment of adults and adolescents with severe COVID-19Read More…

23Sep/22

Creative Biolabs Attended the 13th World Bispecific Summit as An Exhibition Partner

September 23, 2022NewsBispecific Antibody, World Bispecific Summitbiorab

As multispecifics is hailed the fourth wave of drug discovery, with more clinical candidates and commercial success than ever before, the 13th World Bispecific Summit arrived at a pivotal time to deliver the holyRead More…

15Jul/21

Pattern and Trend of Therapeutic Antibody Discovery

July 15, 2021Antibody Engineering R&D, Therapeutic Antibody R&Dantibody discovery, therapeutic antibodybiorab

Since the first therapeutic antibody Muromonab-CD3 was approved in 1986, more than 100 antibodies have been approved for marketing. Based on their properties, antibodies can be divided into four categories: mouse antibodies,Read More…

05Apr/20

Alternatives to Cope with Lengthy Clinical Development Process for COVID-19

April 5, 2020News, Recombinant Antibody R&DClinical Development, SARS-CoV-2, therapeutic antibodybiorab

The latest update— Cases of COVID-19 in the U.S. at a Glance on April 3, 2020, which include both confirmed and presumptive positive cases of COVID-19 reported to CDC or tested atRead More…

Posts navigation

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • Next »

Categories

  • Antibody Engineering R&D
  • Cancer Immunotherapy
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • CD73 Inhibition: A Promising Strategy for Overcoming Immune Evasion in Colorectal Cancer
  • A Breakthrough in Influenza Defense: Discovering Antibodies for Broad-Spectrum Protection
  • Discovery of Highly Neutralizing Human Antibodies Targeting Pseudomonas aeruginosa for Treatment of Drug-Resistant Infections
  • Two New Strategies Targeting Siglec-7 Show Promise in Treating Ovarian Cancer
  • Researchers Revealed the Feasibility and Clinical Prospects of Targeting SLC7A11 for the Treatment of Osteosarcoma

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News